DexCom (DXCM) Revenue & Revenue Breakdown
DexCom Revenue Highlights
Latest Revenue (Y)
$3.62B
Latest Revenue (Q)
$994.20M
Main Geography (Y)
UNITED STATES
DexCom Revenue by Period
DexCom Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.62B | 24.49% |
| 2022-12-31 | $2.91B | 18.84% |
| 2021-12-31 | $2.45B | 27.08% |
| 2020-12-31 | $1.93B | 30.54% |
| 2019-12-31 | $1.48B | 43.08% |
| 2018-12-31 | $1.03B | 43.58% |
| 2017-12-31 | $718.50M | 25.33% |
| 2016-12-31 | $573.30M | 42.61% |
| 2015-12-31 | $402.00M | 55.09% |
| 2014-12-31 | $259.20M | 62.00% |
| 2013-12-31 | $160.00M | 60.16% |
| 2012-12-31 | $99.90M | 30.99% |
| 2011-12-31 | $76.27M | 56.83% |
| 2010-12-31 | $48.63M | 63.78% |
| 2009-12-31 | $29.69M | 201.82% |
| 2008-12-31 | $9.84M | 112.62% |
| 2007-12-31 | $4.63M | 113.25% |
| 2006-12-31 | $2.17M | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2000-12-31 | - | - |
DexCom generated $3.62B in revenue during NA 2023, up 24.49% compared to the previous quarter, and up 351.13% compared to the same period a year ago.
DexCom Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $994.20M | -1.01% |
| 2024-06-30 | $1.00B | 9.04% |
| 2024-03-31 | $921.00M | -10.97% |
| 2023-12-31 | $1.03B | 6.10% |
| 2023-09-30 | $975.00M | 11.90% |
| 2023-06-30 | $871.30M | 17.51% |
| 2023-03-31 | $741.50M | -9.04% |
| 2022-12-31 | $815.20M | 5.93% |
| 2022-09-30 | $769.60M | 10.54% |
| 2022-06-30 | $696.20M | 10.72% |
| 2022-03-31 | $628.80M | -9.94% |
| 2021-12-31 | $698.20M | 7.38% |
| 2021-09-30 | $650.20M | 9.26% |
| 2021-06-30 | $595.10M | 17.84% |
| 2021-03-31 | $505.00M | -11.23% |
| 2020-12-31 | $568.90M | 13.58% |
| 2020-09-30 | $500.90M | 10.87% |
| 2020-06-30 | $451.80M | 11.53% |
| 2020-03-31 | $405.10M | -12.47% |
| 2019-12-31 | $462.80M | 16.78% |
| 2019-09-30 | $396.30M | 17.81% |
| 2019-06-30 | $336.40M | 19.93% |
| 2019-03-31 | $280.50M | -17.01% |
| 2018-12-31 | $338.00M | 26.73% |
| 2018-09-30 | $266.70M | 9.98% |
| 2018-06-30 | $242.50M | 31.51% |
| 2018-03-31 | $184.40M | -16.56% |
| 2017-12-31 | $221.00M | 19.72% |
| 2017-09-30 | $184.60M | 8.21% |
| 2017-06-30 | $170.60M | 19.89% |
| 2017-03-31 | $142.30M | -16.88% |
| 2016-12-31 | $171.20M | 15.21% |
| 2016-09-30 | $148.60M | 8.23% |
| 2016-06-30 | $137.30M | 18.16% |
| 2016-03-31 | $116.20M | -11.16% |
| 2015-12-31 | $130.80M | 24.33% |
| 2015-09-30 | $105.20M | 12.88% |
| 2015-06-30 | $93.20M | 28.02% |
| 2015-03-31 | $72.80M | -13.64% |
| 2014-12-31 | $84.30M | 22.17% |
| 2014-09-30 | $69.00M | 17.35% |
| 2014-06-30 | $58.80M | 24.84% |
| 2014-03-31 | $47.10M | -8.90% |
| 2013-12-31 | $51.70M | 20.51% |
| 2013-09-30 | $42.90M | 19.83% |
| 2013-06-30 | $35.80M | 20.95% |
| 2013-03-31 | $29.60M | -11.02% |
| 2012-12-31 | $33.27M | 44.08% |
| 2012-09-30 | $23.09M | -1.54% |
| 2012-06-30 | $23.45M | 16.70% |
| 2012-03-31 | $20.09M | -10.37% |
| 2011-12-31 | $22.42M | 22.83% |
| 2011-09-30 | $18.25M | -14.77% |
| 2011-06-30 | $21.42M | 51.10% |
| 2011-03-31 | $14.17M | -9.35% |
| 2010-12-31 | $15.64M | 34.05% |
| 2010-09-30 | $11.66M | -1.04% |
| 2010-06-30 | $11.79M | 23.48% |
| 2010-03-31 | $9.54M | -8.84% |
| 2009-12-31 | $10.47M | 44.25% |
| 2009-09-30 | $7.26M | 7.52% |
| 2009-06-30 | $6.75M | 29.53% |
| 2009-03-31 | $5.21M | 27.96% |
| 2008-12-31 | $4.07M | 112.14% |
| 2008-09-30 | $1.92M | -3.13% |
| 2008-06-30 | $1.98M | 6.44% |
| 2008-03-31 | $1.86M | - |
DexCom generated $994.20M in revenue during Q3 2024, up -1.01% compared to the previous quarter, and up 114.11% compared to the same period a year ago.
DexCom Revenue Breakdown
DexCom Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $2.63B | $2.14B | $1.85B | $1.51B | $1.16B |
| Non-US | $997.00M | $767.80M | $599.10M | $417.20M | $314.50M |
Latest
DexCom's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (72.48%), and Non-US (27.52%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $292.30M | $272.40M | $265.40M | $261.40M | $254.70M | $215.50M | $208.80M | $196.20M | $185.20M | $177.60M | $181.10M | $160.60M | $133.60M | $123.80M | $117.40M | $102.30M | $84.70M | $112.80M | $86.90M | $87.50M |
| UNITED STATES | $701.90M | $731.90M | $769.10M | $713.60M | $616.60M | $526.00M | $606.40M | $573.40M | $511.00M | $451.20M | $517.10M | $489.60M | $461.50M | $381.20M | $451.50M | $398.60M | $367.10M | $292.30M | $375.90M | $308.80M |
Latest
DexCom's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (70.60%), and Non-US (29.40%).
DexCom Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.63B |
| MDT | Medtronic | $32.36B | $8.40B |
| EW | Edwards Lifesciences | $6.00B | $1.35B |
| DXCM | DexCom | $3.62B | $994.20M |
| ZBH | Zimmer Biomet | $1.94B | $143.40M |
| PODD | Insulet | $1.70B | $372.60M |
| IART | Integra LifeSciences | $1.54B | $380.83M |
| PEN | Penumbra | $1.06B | $301.04M |
| TNDM | Tandem Diabetes Care | $747.72M | $221.91M |
| INSP | Inspire Medical Systems | $624.80M | $203.19M |
| INMD | InMode | $492.05M | $80.28M |